Eli Lilly and (NYSE:LLY) Downgraded by StockNews.com to Buy

StockNews.com downgraded shares of Eli Lilly and (NYSE:LLYGet Rating) from a strong-buy rating to a buy rating in a research report released on Friday.

Several other brokerages also recently commented on LLY. SVB Leerink assumed coverage on Eli Lilly and in a report on Monday, May 23rd. They set an outperform rating and a $341.00 target price for the company. Barclays upped their price target on Eli Lilly and from $333.00 to $355.00 and gave the company an overweight rating in a research report on Thursday, July 7th. Morgan Stanley upped their price target on Eli Lilly and from $369.00 to $395.00 and gave the company an overweight rating in a research report on Friday, July 8th. JPMorgan Chase & Co. upped their price target on Eli Lilly and from $340.00 to $355.00 in a research report on Wednesday, June 1st. Finally, The Goldman Sachs Group upped their price target on Eli Lilly and from $234.00 to $264.00 and gave the company a neutral rating in a research report on Tuesday, April 12th. Three analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat, Eli Lilly and currently has an average rating of Moderate Buy and a consensus price target of $316.06.

Eli Lilly and Trading Down 1.5 %

Shares of LLY stock opened at $301.32 on Friday. The company has a debt-to-equity ratio of 1.60, a quick ratio of 0.98 and a current ratio of 1.27. Eli Lilly and has a 1 year low of $220.20 and a 1 year high of $335.33. The stock has a fifty day moving average of $316.10 and a two-hundred day moving average of $289.01. The firm has a market capitalization of $286.30 billion, a PE ratio of 48.06, a price-to-earnings-growth ratio of 2.26 and a beta of 0.35.

Eli Lilly and (NYSE:LLYGet Rating) last announced its quarterly earnings data on Thursday, August 4th. The company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.86 by ($0.61). The firm had revenue of $6.49 billion during the quarter, compared to analyst estimates of $6.85 billion. Eli Lilly and had a net margin of 19.58% and a return on equity of 85.10%. The company’s quarterly revenue was down 3.7% compared to the same quarter last year. During the same quarter last year, the company earned $1.87 EPS. As a group, research analysts expect that Eli Lilly and will post 7.98 EPS for the current year.

Eli Lilly and Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 9th. Investors of record on Monday, August 15th will be paid a dividend of $0.98 per share. The ex-dividend date is Friday, August 12th. This represents a $3.92 annualized dividend and a yield of 1.30%. Eli Lilly and’s payout ratio is 62.52%.

Insider Activity at Eli Lilly and

In related news, major shareholder Lilly Endowment Inc sold 80,761 shares of the stock in a transaction that occurred on Monday, May 16th. The stock was sold at an average price of $302.53, for a total transaction of $24,432,625.33. Following the completion of the sale, the insider now owns 105,493,049 shares in the company, valued at approximately $31,914,812,113.97. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction that occurred on Wednesday, June 1st. The stock was sold at an average price of $313.44, for a total value of $313,440.00. Following the completion of the transaction, the chief accounting officer now directly owns 6,274 shares of the company’s stock, valued at approximately $1,966,522.56. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Lilly Endowment Inc sold 80,761 shares of the stock in a transaction that occurred on Monday, May 16th. The stock was sold at an average price of $302.53, for a total value of $24,432,625.33. Following the completion of the transaction, the insider now directly owns 105,493,049 shares of the company’s stock, valued at $31,914,812,113.97. The disclosure for this sale can be found here. Insiders sold a total of 1,195,396 shares of company stock worth $380,134,601 in the last 90 days. 0.12% of the stock is owned by company insiders.

Institutional Investors Weigh In On Eli Lilly and

A number of hedge funds and other institutional investors have recently bought and sold shares of LLY. Cordant Inc. acquired a new stake in Eli Lilly and during the 1st quarter valued at $25,000. AllSquare Wealth Management LLC acquired a new stake in Eli Lilly and during the 4th quarter valued at $28,000. HWG Holdings LP acquired a new stake in shares of Eli Lilly and in the 4th quarter valued at $28,000. Icapital Wealth LLC acquired a new stake in shares of Eli Lilly and in the 1st quarter valued at $28,000. Finally, Castle Wealth Management LLC acquired a new stake in shares of Eli Lilly and in the 2nd quarter valued at $28,000. 82.75% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Profile

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Recommended Stories

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.